Ninjacof XG Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting with acute or subacute cough may be prescribed Ninjacof XG — a codeine phosphate (8 mg) / guaifenesin (200 mg) per 5 mL oral solution manufactured by Centurion Labs. While this brand-name product may suit certain clinical scenarios, prescribers should be aware of the supply landscape in 2026 to help patients avoid delays in treatment.

Current Supply Status as of 2026

Ninjacof XG is not listed on the FDA's drug shortage database as of 2026. However, anecdotal reports from patients and pharmacies indicate that localized stocking gaps are common. This is not unique to Ninjacof XG — it reflects broader trends in opioid cough preparation availability that have emerged since the tightening of prescribing regulations following the opioid epidemic.

Key supply factors to understand:

• DEA annual manufacturing quotas. The DEA sets manufacturing quotas for all controlled substances, including codeine. These quotas can limit the volume of product available in a given calendar year.
• Pharmacy stocking policies. Chain pharmacies have implemented stricter controls on opioid dispensing, including reduced SKU counts for opioid-containing cough preparations. Some pharmacies actively limit which opioid cough syrups they stock.
• Centurion Labs' distribution footprint. Ninjacof XG is produced by a smaller specialty manufacturer. Its distribution network is narrower than that of high-volume generic manufacturers, which means not all pharmacy wholesalers carry it in stock at all times.

Controlled Substance Prescribing Considerations

Ninjacof XG is a Schedule V controlled substance (cough preparation with codeine per DEA guidelines). Prescribers must hold a valid DEA registration to prescribe it. Key prescribing considerations:

• Schedule V products typically allow for refills (unlike Schedule II), but refill rules vary by state
• Not indicated for patients under 18 years of age — the FDA restricted opioid cough suppressants in pediatric populations
• Use with caution in patients with respiratory compromise, sleep apnea, or substance use disorder history
• Avoid concurrent prescribing with benzodiazepines, other opioids, or CNS depressants without clear clinical justification and patient counseling

Therapeutic Alternatives When Ninjacof XG Is Unavailable

When prescribing Ninjacof XG and your patient reports inability to fill, consider the following alternatives:

• Generic codeine/guaifenesin oral solution — same active ingredients, broader availability. Consider writing for the generic if DAW is not clinically required.
• Benzonatate 100 mg or 200 mg capsules — non-opioid, non-controlled, widely available. Effective for many patients with cough of respiratory origin.
• Guaifenesin extended-release (Mucinex 600 mg or 1200 mg) — for patients where mucus clearance is the primary clinical goal.
• Dextromethorphan-containing preparations — OTC availability makes these a convenient bridge option.

Practical Prescribing Recommendation for 2026

Given the stocking variability of Ninjacof XG, consider the following practice adjustments:

1. Write for the generic when possible. Prescribing "codeine phosphate/guaifenesin oral solution" without specifying Ninjacof XG gives the pharmacist flexibility to fill with any stocked equivalent.
2. Counsel patients proactively. Let patients know that this medication may require calling multiple pharmacies and that a generic substitution is clinically equivalent.
3. Direct patients to medfinder. medfinder calls pharmacies near your patient on their behalf to locate which ones have the medication in stock. This saves patients significant time and reduces call-back volume to your office.

Key Takeaways for Clinicians

• No active FDA shortage for Ninjacof XG in 2026, but localized stocking gaps are common
• Generic codeine/guaifenesin oral solution is therapeutically equivalent and more widely available
• Non-opioid alternatives (benzonatate, dextromethorphan) are appropriate for many patients with acute cough
• Consider writing generic prescriptions to reduce patient barriers to access